Fig. 5.

Chronic administration of the 5-HT2A selective inverse agonist SR46349b, but not pimavanserin, up-regulates 5-HT_2A receptor level but had no significant effect on PCP-induced hyperlocomotor response in C57BL/6J mice, A and B, immunoblot (IB) of immunoprecipitates (IP) from cortex membrane lysates. The same blots were reprobed for transferrin receptor as loading controls. C and D, densitometry of immunoblots of immunoprecipitates from n = 4 mice/treatment group. *, p < 0.05, unpaired t test. E and F, B_max estimates were obtained by performing [³H]ketanserin saturation binding on cortical membrane homogenates. Data are presented as mean ± S.E.M. (n = 6/group), *, p < 0.05, unpaired t test. G and H, chronic treatment with vehicle or SR46349b or pimavanserin (5.0 mg/kg, 14 days) had no significant effect on PCP (6.0 mg/kg)-induced hyperactivity in C57BL/6J mice (n = 6–8/group). Data are expressed as mean total horizontal distance traveled in 5-min bins over 90 min after PCP administration (±S.E.M.). *, p < 0.05, unpaired t test. MW, molecular weight; Veh, vehicle.